{"id":3619,"date":"2009-09-04T11:45:07","date_gmt":"2009-09-04T08:45:07","guid":{"rendered":"http:\/\/www.ced.org.tr\/?p=3619"},"modified":"2009-09-04T11:45:07","modified_gmt":"2009-09-04T08:45:07","slug":"pfizera-2-3-milyar-dolarlik-ceza","status":"publish","type":"post","link":"http:\/\/www.ced.org.tr\/?p=3619","title":{"rendered":"Pfizer\u2019a 2.3 milyar dolarl\u0131k ceza"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt;\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\"><strong>Uluslararas\u0131 ila\u00e7 devi Pfizer, 2.3 milyar <\/strong><\/span><a name=\"aspx1\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\"><strong>dolar<\/strong><\/span><\/a><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\"><strong> tazminat \u00f6deyecek<\/strong><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt;\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt;\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\">ABD\u2019de baz\u0131 ila\u00e7lar\u0131n sat\u0131\u015flar\u0131nda aldat\u0131c\u0131 y\u00f6ntemleri kullanarak pazarlama yapt\u0131\u011f\u0131 iddias\u0131yla su\u00e7lanan Pfizer, su\u00e7lamalar\u0131 kabul edip anla\u015fma yoluna gitti. \u015eirket bu anla\u015fmayla birlikte 2.3 milyar dolarl\u0131k cezay\u0131 \u00f6demeyi kabul etmi\u015f oldu.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt;\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\">Re\u00e7eteyle sat\u0131lmas\u0131 gereken ila\u00e7lar\u0131n ruhsats\u0131z olarak pazarlanarak, sat\u0131\u015f\u0131 yap\u0131ld\u0131\u011f\u0131 iddias\u0131yla \u015firket hakk\u0131nda cezai soru\u015fturma ba\u015flatm\u0131\u015ft\u0131. Soru\u015fturma, uygulamalara tepki g\u00f6steren alt\u0131 \u015firket yetkilisinin \u015fikayeti \u00fczerine ba\u015flam\u0131\u015ft\u0131. Bu ki\u015filere de 100 milyon dolar\u0131 a\u015fk\u0131n bir \u00f6deme yap\u0131l\u0131yor.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt;\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\">Pfizer\u2019in ila\u00e7lar\u0131 re\u00e7etelendirmeye te\u015fvik etmek pek \u00e7ok yetkili isme r\u00fc\u015fvet ve hediyeler verdi\u011fi de \u00f6ne s\u00fcr\u00fcl\u00fcyordu. <\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt;\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\">Ara\u015ft\u0131rma konusu olan ila\u00e7lar anti-enflamatuar Bextra, antipsikotik Geodon, antibiyotik Zyvox ve epilepsi tedavisinde kullan\u0131lan Lyrica oldu.<\/p>\n<p><strong>T\u00fcm davalar kapanacak<\/strong><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt;\"><span style=\"font-family: Times New Roman; color: #000000; font-size: small;\">Pfizer, yan kurulu\u015fu olan \u015firket arac\u0131l\u0131\u011f\u0131yla, baz\u0131 ila\u00e7lar\u0131, izin verilen hastal\u0131klar\u0131n tedavisi d\u0131\u015f\u0131nda kullan\u0131lmak \u00fczere hastalara ve hekimlere pazarlama faaliyetlerinde bulunmas\u0131 \u00fczerine, dava a\u00e7\u0131lm\u0131\u015ft\u0131. Yap\u0131lan anla\u015fma ABD\u2019de Adalet Bakanl\u0131\u011f\u0131 ve \u015firket yetkilileri taraf\u0131ndan imzaland\u0131. Sulh \u00e7\u00f6z\u00fcm\u00fc olarak da adland\u0131r\u0131lan 2.3 milyar dolarl\u0131k anla\u015fmayla hukuki s\u00fcre\u00e7 tamamlanacak.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Uluslararas\u0131 ila\u00e7 devi Pfizer, 2.3 milyar dolar tazminat \u00f6deyecek \u00a0 ABD\u2019de baz\u0131 ila\u00e7lar\u0131n sat\u0131\u015flar\u0131nda aldat\u0131c\u0131 y\u00f6ntemleri kullanarak pazarlama yapt\u0131\u011f\u0131 iddias\u0131yla&#46;&#46;&#46;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3619","post","type-post","status-publish","format-standard","hentry","category-ced"],"aioseo_notices":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/3619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3619"}],"version-history":[{"count":0,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/3619\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3619"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}